Apixaban for the prevention of stroke in atrial fibrillation

References

• Go A, Hylek E, Phillips K et al. Prevalence of diagnosed atrial fibrillation in adults. JAMA285(18), 2370–2375 (2001).
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB et al.Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke22, 983–988 (1991).
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med.146, 857–867 (2007).
   PubMed Web of Science ®Google Scholar
• Wysowski SK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Int. Med.167(13), 1414–1419 (2007).
   PubMed Web of Science ®Google Scholar
• Franco V, Polanczyk CA, Clausell N et al. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am. J. Med.116(10), 651–656 (2004).
   PubMed Web of Science ®Google Scholar
• Martins MA, Carols PP, Ribeiro DD et al. Warfarin drug interactions: a comparative evaluation of the lists provided by five information sources. Eur. J. Clin. Pharmacol.67(12), 1301–1308 (2011).
   Google Scholar
• Baker WL, Cios DA, Sander SD et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J. Manag Care Pharm.15(3), 244–252 (2009).
   PubMed Web of Science ®Google Scholar
• Mann KG, Brummel K, Butenas S. What is all that thrombin for? J. Thromb. Haemost.1(7), 1504–1514 (2003).
   PubMed Web of Science ®Google Scholar
• Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature246(5432), 355–357 (1973).
   PubMed Web of Science ®Google Scholar
• Pinto DJ, Orwat MJ, Koch S et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation Factor Xa. J. Med. Chem.50(22), 5339–5556 (2007).
   PubMed Web of Science ®Google Scholar
• Perzborn E, Strassburger J, Wilmen A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939 – an oral, direct Factor Xa inhibitor. J. Thromb. Haemost.3(3), 514–521 (2005).
   PubMed Web of Science ®Google Scholar
• He K, Luettgen JM, Zhang D et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective Factor Xa inhibitor. Eur. J. Drug Metab. Pharmacokinet.36(3), 129–139 (2011).
   PubMed Web of Science ®Google Scholar
• Barrett YC, Wang Z, Frost C et al. Clinical laboratory measurement of direct Factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb. Haemost.104(6), 1263–1271 (2010).
   PubMed Web of Science ®Google Scholar
• Raghavan N, Frost CE, Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab. Dispos.37(1), 74–81 (2009).
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang D, Raghavan N et al.In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab. Dispos.38(3), 448–458 (2010).
   PubMed Web of Science ®Google Scholar
• Walenga JM, Adiquzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int. J. Clin. Pract.64(7), 956–967 (2010).
   PubMed Web of Science ®Google Scholar
• Frost C et al. Food does not affect the pharmacokinetics of apixaban, an oral, Factor Xa inhibitor. Can. J. Clin. Pharmacol.15(3), e469 (2008).
   Google Scholar
• Frost C, Song Y, Barrett YC et al. Direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Presented at: XXIII Congress of the International Society on Thrombosis and Haemostasis. Kyoto, Japan, July 23–28 2011.
   Google Scholar
• Lassen MR, Davidson BL, Gallus A et al. The efficacy and safety of apixaban, an oral, direct Factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost.5(12), 2368–2375 (2007).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med.361(6), 594–604 (2009).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet375(9717), 807–815 (2010).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob A, Gallus GE et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med.363(26), 2487–2498 (2010).
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med.365(8), 699–708 (2011).
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Leizorovicz A, Kakkar AK et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N. Engl. J. Med.365(23), 2167–2177 (2011).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med.364(9), 806–817 (2011).
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.365(11), 981–992 (2011).
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med.365(10), 883–891 (2011).
   PubMed Web of Science ®Google Scholar
• Melnikova I. The anticoagulants market. Nat. Rev. Drug Discov.8(5), 353–354 (2009).
   PubMed Web of Science ®Google Scholar